期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

达肝素钠给药后激活全血凝固时间、抗-Ⅱa及抗-Xa活性的变化

下载PDF
导出
作者 张小雷 崔炜 鲁静朝 都军 刘凡 谷国强 谢瑞芹 杨晓红 杨秀春
机构地区 河北医科大学第二医院河北省心脑血管病研究所心内科
出处 《临床荟萃》 CAS 北大核心 2007年第7期501-502,共2页 Clinical Focus
基金 河北省重大疾病和常见病预防治疗关键技术研究专项(06276107D)
关键词 冠状动脉疾病 肝素 低分子量
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献12

  • 1Borentain M, Montalescot G, Bouzamondo A, et al. Lowmolecular-weight heparin vs unfractionated heparin in percutaneous coronary intervention: a combined analysis[J].Catheter Cardiovasc Interv,2005,65(2):212-221.
  • 2Madan M, Radhakrishnan S, Reis M, et al. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial)[J]. Am J Cardiol, 2005, 95(11) .1295-1301
  • 3陈纪林,陈珏,乔树宾,吴永健,戴军,袁晋青,秦学文,姚民,杨跃进,高润霖.冠心病介入治疗中应用低分子肝素与普通肝素的随机对照研究[J].中华心血管病杂志,2006,34(2):127-129. 被引量：17
  • 4曹俊杰,阚长利,王义围,周健,张晓君,杨桂梅.低分子肝素与普通肝素在冠状动脉介入治疗中的安全性和有效性观察[J].临床荟萃,2006,21(19):1418-1418. 被引量：3
  • 5陈纪林.心血管病病人应用低分子肝素要规范化[J].中华医学杂志,2005,85(13):868-869. 被引量：8
  • 6Hirsh J, Raschke R. Heparin and low-molecular-weight heparin:the Seventh ACCP Conference of Antithrombotic and Thrombalytin Therapy [J]. Chest, 2004, 126 (suppl) : 188S-203S.
  • 7Marmur JD, Anand SX,Bagga RS, et al. The activated clotting time can he used to monitor the low molecular weight heparin daheparin after intravenous administration [J]. J Am Coil Cardiol,2003,41(3) :394-402.
  • 8Wilson JM, Gilbert J, Harlan M, et al. High-dose intravenous dalteparin can be monitored effectively using standard coagulation times [J]. Clin Appl Thrombosis/Hemostasis,2005,11(2):127-138.
  • 9Cavusoglu E, Lakhani M, Marmur JD. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration[J]. J Invasive Cardiol, 2005,17(8) :416-421.
  • 10Kakkar VV. Low-dose heparin to low molecular weight heparin prophylaxis: in pursuit of excellence-a personal perspective[J]. J Thromb Haemost, 2005,3(2) :195-209.

二级参考文献15

  • 1Cohen M,Demers C,Gurfinkel EP,et al.A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.N Engl J Med,1997,337:447-452.
  • 2Antman EM,McCabe CH,Gurfinkel EP,et al.Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction.Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.Circulation,1999,100:1593-1601.
  • 3Serebruany VL,Malinin AI,Callahan KP,et al.Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction:the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.Am Heart J,2003,145:636-642.
  • 4Wallentin L,Goldstein P,Armstrong PW,et al.Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting:the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.Circulation,2003,108:135-142.
  • 5Collet JP,Montalescot G,Lison L,et al.Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.Circulation,2001,103:658-663.
  • 6Kereiakes DJ,Montalescot G,Antman EM,et al.Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention:an expert consensus.Am Heart J,2002,144:615-624.
  • 7Choussat R,Montalescot G,Collet JP,et al.A unique,low dose of intravenous enoxaparin in elective percutaneous coronary intervention.J Am Coll Cardiol,2002,40:1943-1950.
  • 8Montalescot G,Collet JP,Tanguy ML,et al.Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.Circulation,2004,110:392-398.
  • 9Goodman SG, Cohen M, Bigonzi F, et al.Efficacy and safety of subcutaneous Enoxaparin in Non-Q-Wave Coronary Events ESSENCE (1-Year Results) randomized trial of low-molecular-weight heparin (enoxaparin) vs unfractionated heparin for unstable coronary artery disease 1-year results of the ESSENCE atudy. J Am Coll Cardiol, 2000,36:693-698.
  • 10Antman EM, McCabe CH, Gurfinkel EP, et al. Tbrombolysis in myocardial infarction -IIB TIMI-11B enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction.results of the TIMI IIB Trial. Circulation, 1999,100:1593-1601.

共引文献24

临床荟萃
2007年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部